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FR139317 RES-701-1 Nitroglycerin Plastaglandin El
200/Lglkglmin 100 /Lglkg/min 10 /Lglkg/min 0,4 /Lglkglmin
Endothelin Receptor Antagonists in a Beagle
Model of Pulmonary Hypertension: Contribution
to Possible Potential Therapy?
Baseline
* Significant difference between baseline and drug infusions at P < 0,05 levels. MSAP:
mean systemic arterial pressure. MPAP: mean pulmonary arterial pressure. SVR: sys·
temic vascular resistance. PVR: pulmonary vascular resistance
MSAP 106±5
(mmHg)
MPAP 332±59
(mmHg)
SVR Idynesl 4685 ± 439
s/em 5)
PVR{dynes/1237±441
s/em 5)
Conclusions: ETA receptor antagonists decrease pulmonary arterial pres-
sure in a beagle model and therefore may be clinically useful for therapy of
pulmonary hypertension.
in this model, U74389G attenuates the systolic and diastolic dysfunction of
myocardial stunning, most likely by protecting the lipid component of cell
membranes from peroxidation by oxygen-derived metabolites.
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The idealvasodilator for pulmonary hypertension (PH) would decrease pul-
monary arterial pressure with minimal systemic hypotension. The present
study was undertaken to investigate the pharmacologic effect of endothelin
receptor antagonists on cardiopulmonary hemodynamics in an animal model
of PH. We recently developed a beagle model of PH which allows accurate
determination of cardiopulmonary hemodynamics and which is associated
with elevated plasma endothelin-1 concentrations similar to PH in humans.
Twelve beagles (PH, n = 6; and Control, n = 6) were studied during base-
line conditions and during right atrial infusion of FR139317 (the ETA recep-
tor antagonist). RES-701-1 (the ETB receptor antagonist). nitroglycerin, and
prostaglandin E1. PH was induced in experimental animals 8 weeks after
an injection of 3 mglkg dehydromonocrotaline. The table showed hemody-
namic values of PH beagles at baseline and during drug infusion. FR139317
lowered pulmonary and systemic arterial pressure both in pulmonary hyper-
tensive and control animals, with a significantly greater effect on pulmonary
arterial pressure in pulmonary hypertensive animals. RES-701-1 increased
pulmonary arterial pressure only in PH. Nitroglycerin depressed pulmonary
and systemic arterial tone equally well in controls and animals with PH.
Prostaglandin El produced a greater decrease in systemic arterial pressure
in pulmonary hypertensive than in normal animals, despite same effect on
pulmonary arterial pressure in both.
1901-1131
PHARMACOLOGY - BASIC
ACE Inhibition (Quinapril) Modulates Central
Vasopressin in the Rat
ABSTRACfS
Attenuation of Myocardial Stunning by a Novel
Nonglucocorticoid 21-Aminosteroid Inhibitor of
Lipid Peroxidation
(ns vs 0). Conclusion: 3D reconstruction can improve spatial appreciation of
the shape of thrombi and accurately measure their volumes. This approach,
suitable for epivascular or transvenous imaging, could potentially be used to
study thrombus formation and lysis in research and clinical studies.
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The beneficial effects of ACE inhibitors (ACE I) in heart failure and hyperten-
sion appear to be mediated not only by their influence on circulating ACE or
tissue ACE in the heart. Previous studies have also implicated the brain as
a possible site of actions for ACEI, e.g. by modifying central cardiovascular
mechanisms. Their effects on central vasopressin (AVP), which is an impor-
tant neurotransmitter in central cardiovascular regulation, are not known.
Following chronic administration of Quinapril (6 mglkgBW; 6 weeks,
p.o.) ACE activity (in vitro autoradiography using a specific ACE inhibitor
[1251]351A) was markedly inhibited in the thalamus (38%), hypothalamus
(37%). hypophysis (35%). cerebellum (36%) and plexus choroideus (20%)
suggesting Quinapril may cross the blood brain barrier after chronic treat-
ment. To study the influence of ACEI on central vasopressin, we deter-
mined the AVP content of 19 microdissected brain areas in rats treated with
Quinapril. Regarding the hypothalamic AVP-producing nuclei. increased AVP
levels could only been demonstrated in the paraventricular (PVN; Quinapril:
292 ± 197 vs. 2209 ± 568 pglmg protein of controls; p < 0.001). but not in the
supraoptic (SON) and the suprachiasmatic nucleus ISCN). Interestingly, vaso-
pressin synthesizing cells in the PVN project not only to the posterior pituitary
(like SON). but also to the lower brain stem and the spinal cord suggesting
an important role of the PVN in the regulation of the cardiovascular system.
Also, AVP content was sign. reduced in the median eminence (15643 ± 9240
vs. 28321 ± 4969, P < 0.001), where the hormone is mainly concentrated in
the hypothalamo-hypophysial tract. Furthermore, sign. changes were regis-
tered in the central amygdala, in the subcommissural organ and dorsal raphe
nucleus.
Conclusions: Autoradiographic study in vitro indicates that after chronic
treatment Quinapril is able to cross the blood brain barrier and suppress
central ACE activity. ACE inhibition with Quinapril markedly influences vaso-
pressin in important brain areas which are involved in central cardiovascular
regulation. Therefore, central modulatory effects of ACE inhibitor may con-
tribute to their overall therapeutic efficacy.
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There is a lack of data on gender difference in response to the newer an-
tihypertensive medicines. The Amlodipine Cardiovascular Community Trial
was designed to determine the blood pressure (BP) response of patient sub-
groups with mild-moderate hypertension to amlodipine besylate monother-
apy (5-1 0 mg/day). After a 2 week placebo phase, patients received amlodip-
ine for a 4 week efficacy/titration phase followed by a 12 week maintenance
phase. Goal BP was defined as a decrease in diastolic BP by 10 mmHg or
more plus a diastolic BP of less than 90 mmHg. Baseline systolic BP in mmHg
was 153 ± 16 and 155 ± 16 and diastolic BP 101 ± 4 and 100 ± 4 for males
In = 702) and females (n = 382), respectively. Decreases in BP at 4 weeks
were greater in females than males for both systolic (-19 vs -15 mmHg, p
< 0.0001) and diastolic BP (-14 vs -12 mmHg, p < 0.0001). Results were
maintained at 12 weeks. Ninety-one percent of females achieved goal BP
compared to 83% of men (p = 0.001). The greater response to amlodipine by
women remained significant after adjusting for: age, weight, dose (mglkg),
baseline BP. and drug compliance (99% in both women and men). There was
no difference in decrease in systolic and diastolic BP for women on hormone
replacement (-18 and -14 mmHg) versus those not on hormone replace-
ment (-19 and -14 mmHg). Thus, hormone replacement in women did not
account for the gender difference in BP response. Women reported edema
Abel E. Moreyra, Robert S. Conway, Wen H. Chen, Windsor Tlng, John B. Kostis.
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Lipid peroxidation induced by oxygen free radicals has been implicated
in myocardial dysfunction during reperfusion. The effect of a new 21-
aminosteroid (Lazaroid, U74389G) that inhibits lipid peroxidation was stud-
ied in isolated, isovolumic rat hearts subjected to 20 min of normothermic
ischemia and subsequent repefusion for 30 min. Male Sprague-Dawley rats
(350-400 g) were randomized into three groups. Group 1 (Control; n = 13)
received vehicle before sacrifice and drug-free reperfusion, group 2 (Pretreat-
ment; n = 11) received 6 mglkg (iv) U74389G 30 min prior to sacrifice, and
group 3 (Reperfusion; n = 11) received 5 /LM U74389G in the reperfusion
solution. LV developed pressure (LVDP) and end-diastolic pressure ILVEDP)
were measured; maximum +dP/dt and the time constant of relaxation, Tau
(T). were calculated.
LVDP +dPldt LVEDP Tau
ImmHg) ImmHglsec) ImmHg) (msec)
Control group
Baseline 127 ± 6 2892 ± 127 5 ± 1 23 ± 1
30 min reperfusion 66 ± 5 1673 ± 140 30 ± 6 58 ±9
Pretreatment group
Baseline 122 ± 3 2893 ± 97 7 ± 1 24 ± 1
30 min reperfusion 112±3** 3171 ± 159** 14 ± 3* 28 ± 3*
Reperfusion group
Baseline 124 ± 4 2744 ± 77 5± 1 21 ± 1
30 min reperfusion 108 ± 5** 2785 ± 129** 14± 5* 32 ± 9*
*p < 0.05 VS. Control group, 30 min reperfusion; **p < 0.01 VS. Control group, 30 min
reperfusion
Conclusion: Whether administered before ischemia or during reperfusion
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Women Have a Higher Response Rate than Men
to the Antihypertensive Calcium Channel
Blocker Amlodipine
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VALVULAR DISEASE
Mitral Valve Prolapse: Is it Associated with Acute
Ischemic Neurologic Events?
PBV (I vs II)
NHV (III vS IV)
PBV-Ca2+ and NHV-Ca2+ (II vs III)
PBV-Ca2+ vs NHV-NonCa2+
* Significant p value by Fisher's Exact Test
Cellular Expression of Matrix Proteins Mediates
Calcification in Native Human and Bioprosthetic
Heart Valves
Sanjay Srivatsa, Philip Harrity, William Edwards, Christopher Johnson,
Lorraine Fitzpatrick. Mayo Clinic and Mayo Foundation, Rochester, MN
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A high frequency of association has previously been reported between acute
ischemic neurological events and mitral valve prolapse (MVP), especially in
young patients I<45 years old), primarily based on M-mode scans. Criteria for
diagnosing MVp, however, have subsequently changed based on 3D analysis
of valve shape and clinical correlations, greatly decreasing its prevalence. It
is therefore necessary to reconsider associations previously described using
nonspecific M-mode and two-dimensional (2D) echo criteria. We retrospec-
tively reviewed all echo studies performed from 1985 to 1994 in patients
<45 years old referred by their physician because of stroke or transient is-
chemic attack looking for source of embolus. Patients with known or poten-
tial sources such as prosthetic heart valves, intracardiac masses, dilated or
aneurysmal LV. or congenital heart defects were excluded. MVP was evalu-
ated using 2D echo criteria now widely accepted (in long-axis views, exclud-
ing nonspecific anterior leaflet displacement in the 4-chamber view; these
criteria correlate with valve dysfunction and valve-related complications). Re-
sults: Ofthe 244 patients evaluated, only 3 (1.2%) had MVP (anterior, posterior
and bileaflet with thin valves and normal LA size). All 3 patients also had a
patent foramen ovale with shunt. Discussion: Earlier studies using less spe-
cific M-mode criteria found MVP in up to 40% of young patients with stroke
or TIA, but also in 7-21 % of otherwise healthy individuals. In contrast, the
very low prevalence of MVP in the present group of patients, despite referral
for echocardiography (potential bias towards the diagnosis), suggests the
association is much smaller, possibly at the level of random association.
Conclusion: The linkage ofMVP and acute ischemic neurological events in
the young, therefore, could not be demonstrated by more recent validated
and accepted 2D echo criteria in an echocardiographic referral population.
Dystrophic mineralization remains the leading cause of valve stenosis and
failure in native human (NHV) and porcine bioprosthetic (PBV) heart valves.
We hypothesized that expression of noncollagenous matrix proteins (MP)
that induce skeletal mineralization may orchestrate valvular calcification
(Ca 2+). 18 porcine PBV and 13 NHV obtained during replacement surgery
were analysed for cells, calcium, fibrosis and vessels. Immunostaining for
macrophages, T-cells, a-smooth muscle (SM) actin, osteopontin (OP), os-
teocalcin (OC) and osteonectin (ON) was performed with non-immune sera
as controls. In situ hybridization analysis utilized antisense oligonucleotide
probes for OR OC, ON and sense controls. Results were compared to known
positive/negative tissue controls and normal heart valves. A probe averaged
in situ score was calculated for each valve. MP in situ was graded positive
if ~2 different probes exhibited >5 signal positive cells/slide. Valves were
divided into 4 groups based on presence of calcium: I: PBV non-Ca2+ (n =
8); II: PBV-Ca2+ (n = 10); III: NHV-Ca2+ (n = 8); IV: NHV non-Ca2+ (n = 5). 2
x 2 contingency table analysis of in situ signal status revealed:
Dan Gilon, Ferdlnando S. Buonanno, J. Philip Kistler, Marcia Leavitt, Jane
E. Marshall, Arthur E. Weyman, Robert A. Levine. Massachusetts General Hospital,
Boston, MA
Positive
versus
negative
in situ
Comparison of mean in situ scores revealed significant differences among
groups III vs IV and I vs IV PBV age (p < 0.001) and NHV cellularity (p < 0.003)
correlated with calcium. For all valves: OR OC and ON mRNA expression lo-
calized with calcification and cellular infiltration; immunostaining identified
macrophages, OR OC and ON at the calcification front; SM were associated
with valve edges and cuspal Ca2+ Conclusions: (1) Cell-mediated calcifica-
tion is promoted by matrix protein expression common to PBV and NHV;
(2) matrix protein mRNA expression is quantitatively related to extent and
localization of valvular mineralization; (3) macrophage infiltration is closely
associated with matrix protein expression and calcification.
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Coronary Vascular Relaxation Induced by
Testosterone In Vivo is Gender Independent
Tony M. Chou, Krishnankutty Sudhir, Thomas M. Amidon, Peter Collins, Paul
G. Yock, Kanu Chatterjee. University of California, San Francisco, CA
Variables Rest Exercise
Drug-Free Estrogen Drug-Free Estrogen
SBPlmmHg) 142 ± 24 131 ± 21' 186 ± 33 181 ± 31
DP (SBPxHR) 9987 ± 2503 9087 ± 1422' 27300 ± 9079 26432 ± 6821
LVEDD (em) 4.4 ± 0.4 4.4 ± 0.6 4.3 ± 0.4 4.0 ± 0.7
LVESD (em) 3.0 ± 0.6 29 ± 0.7 2.7 ± 0.6 2.5 ± 0.7
Beneficial Effects of Estrogen Replacement
Therapy on Cardiovascular Hemodynamics in
Postmenopausal Women
Millie Lee, Stephanie R. Bruce, Nan Garber, Henry Wu, George Shapiro, Marco Di
Tullio, Shunichi Homma, Elsa-Grace V. Giardina. Center for Women's Health.
Columbia University. New York, NY
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Estrogen replacement therapy (ERT) in postmenopausal women reduces the
risk of fatal and nonfatal coronary artery disease (CAD). The mechanism of
the beneficial effect is not yet fully explained, although changes in plasma
lipoproteins and a direct vasodilatory effect have been suggested, To inves-
tigate the effect of standard oral ERT. we performed exercise echocardio-
graphy in 11 postmenopausal women (mean age 62 ± 8 years). Subjects
were randomized to 0.625 mg conjugated oral equine estrogen or no active
treatment for 30 days, with crossover after a 4 to 6 week washout period. At
rest and at peak exercise, systolic blood pressure (SBP), heart rate (HR), left
ventricular end-systolic (LVESD) and end-diastolic (LVEDD) diameters were
measured and cardiac double product (DP) calculated at baseline and after
each treatment. The results follow:
more frequently than men. In conclusion, women demonstrated a greater
antihypertensive effect to amlodipine than men; the mechanism for this ob-
servation remains to be determined,
'p < 0.05, 'p ~ 005
Conclusion: Short-term ERT reduces systolic blood pressure, double prod-
uct and LV diameters at rest and after exercise. These observations suggest
that the beneficial mechanism of ERT in postmenopausal women may be
mediated via a reduction in cardiac afterload.
To assess coronary vasoreactive response of testosterone and its relation
to gender, we examined the effect of intracoronary testosterone (10- 10 to
10-6M) on epicardial and resistance coronary arteries in vivo in both male
(5) and female (5) dogs, Changes in average peak flow velocity (APV) were
assessed using a 0.014" Doppler guidewire (Cardiometrics), and epicardial
cross-sectional area (CSA) was measured using a 4.3 F, 30 MHz ultrasound
imaging catheter (CVIS). Guidewire and imaging catheter were positioned
in the left circumflex artery. Testosterone induced a significant increase in
both CSA, APV and calculated volumetric coronary blood flow (CBFI at the
10-7 and 1O-6M concentrations (CSA: 15.2 ± 10.2% increase at 1O-6M (p
= 0.05); APV: 36.4 ± 12.8 increase at 10-7 (p < 0,01) and 73.8 ± 66.8%
increase at 10-6M (p ~ 0.004); CBF: 205% increase at 10-6M (p = 0.04)1.
Coronary vasorelaxation was equal in both males and females. No significant
changes in heart rate or systemic pressure were noted.
Conclusion: We conclude that acute testosterone administration induces
epicardial and resistance coronary artery dilation in vivo and coronary vasore-
laxation is independent of gender.
